04:28 PM EDT, 06/30/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) said late Monday it has struck a deal for up to $275 million of non-dilutive senior secured term loan facility from Hecules Capital (HTGC) to boost its balance sheet.

Dyne said it secured $100 million upfront, with additional $175 million tied to clinical, regulatory and commercial progress.

"We are well-positioned to execute on our plans to deliver functional improvement to the neuromuscular community, as we near a potential US launch in DMD in 2027," said CEO John Cox.